L&T Technology Services, Exponential-e Partner to Jointly Offer ‘New Normal’ Workplace Transformation Solutions
Exponential-e, a UK-based leading & innovative CSP of enterprise connectivity & unified communications services, today entered into a strategic partnership with L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a leading global pure-play engineering services company, to jointly offer workplace transformation solutions to customers working in the post-COVID environment.
In the “new normal” brought on by the pandemic, enterprises are ramping up operations in phases and planning to bring back their workforce, with their health and safety being the top priority. During these times, the need of the hour for companies is to retrofit the workplace with safety solutions on a fully digital foundation that can scale to intelligent buildings/campuses, smart facilities and offices.
According to the partnership, LTTS will offer its latest solution i-BEMS™ Shield, built on the company’s award-winning i-BEMS™ framework, and anchored on Exponential-e’s next-gen composite SDN carrier grade network & cloud infrastructure. The combination of these solutions will accelerate digital transformation of the workplace, across industries through digital technologies and platforms.
LTTS’ Intelligent Building Experience Management System, i-BEMS™ is a modular ‘system-of-systems’ platform that unifies all campus operations under one system and focuses on creating digital experiences and building optimization.
To build future-facing workplaces, i-BEMS™ is deploying Shield, a module within the solution that automates and develops smart systems and provides real-time insights to diagnose inefficiencies for quick decision making. i-BEMS™ Shield’s advanced digital interface redefines contactless interaction and surveillance by enabling temperature detection, face detection and tracking, air quality management, occupancy management and energy management.
Exponential-e, a leader in delivering fast, low latency connectivity, flexible and resilient Cloud solutions and world class IT services, will provide the platform for i-BEMS™ Shield to scale new heights of safety at workspace. The company’s ‘Software Defined-Digital Platform’, anchored on world class SD-WAN hosting the LTTS full stack digital innovation applications has the potential to spawn an ecosystem powered by digital VAS; drones-as-a service, connected cars, video-analytics as a service, AR/VR, gaming, smart cities & intelligent buildings are high in impact & value. Every industry is transforming itself through mobility & digital technologies. The LTTS-Exponential-e partnership accelerates the transformation by enabling a platform-based business federated in structure for companies across industries to collaborate and co-create new markets and revenue generating services.
Lee Wade, Founder & CEO, Exponential-e said, “The needs of businesses in the post-COVID environment is set for a dramatic change. While green quotient and sustainability were focus areas earlier for adopting smart building frameworks for campuses, enterprises now are faced with the urgent need of ensuring a safe and secured workplace environment for their workforces. With increasing customer engagement devices being used to help the modern-day work environment, we provide a software-defined network where functions can be deployed seamlessly. We are pleased to partner with an engineering services leader like LTTS and are confident that together, we will co-develop a value proposition that aligns with the present day needs of businesses in this ‘new normal’ world.”
Gaurav Gupta, Chief Business Officer, Europe, at L&T Technology Services said, “Worldwide the most evident trend to emerge as a fallout of COVID-19 are the disruptive innovations driven by new-age digital technologies. The role of ER&D services in shaping such cutting-edge innovative solutions will only grow. Our strategic partnership with Exponential-e is one such initiative that promises to redefine the smart building ecosystem and we are glad to be the pioneers on this front along with Exponential. This tie-up will lay the foundation for multiple industry leading initiatives on smart and secure workspaces and campuses in the near future.”
About L&T Technology Services Ltd
L&T Technology Services Limited (LTTS) is a publicly listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 69 Fortune 500 companies and 53 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have over 16,600 employees spread across 17 global design centers, 28 global sales offices and 51 innovation labs as of June 30, 2020. For more information, visit https://www.ltts.com/
Exponential-e is a Cloud, Connectivity and Communications pioneer with a difference. From launching the world’s first Virtual private LAN in 2006 on its privately-owned 100GigE secure and super-fast Network, to its recent launch of its Software-Defined Digital Platform (SD-DP). (https://www.exponential-e.com/solutions/digital-transformation-model).
Exponential-e’s commitment to innovation has resulted in it being recognised as one of the fastest-growing private companies in the UK. Exponential-e has also built an extensive solutions portfolio, enabling the creation of services tailored specifically to its customers’ operational needs – whether that be for Private & Public Cloud, Data Centre, Unified Communications, Cyber Security or managed IT Services.
Delivering customer service excellence is at the heart of Exponential-e. That’s why it’s trusted by over 3,000 customers, with 96% reference-ability and an industry-leading Net Promoter Score of 73.
We work to international management standards and are accredited with 8 ISO accreditations. Today, Exponential-e employs 700 staff members across London, Manchester and Chippenham.
L&T Technology Services Limited
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ESMO 2020: Cabometyx ® (cabozantinib) in Combination With Opdivo ® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial19.9.2020 18:30:00 CEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) demonstrated significant improvements across all efficacy endpoints, including overall survival (OS), in previously untreated advanced renal cell carcinoma (RCC).1 Cabometyx® in combination with Opdivo® reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40–0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx® in combination with Opdivo®, median progression-free survival (PFS), the trial’s primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41–0.64], p < 0.0001). In addition, Cabometyx® in combination with Opdivo® demonstrated a superior objective response rate, wit
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 12:55:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 12:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95
Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 09:30:00 CEST | Press release
Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu
Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 08:00:00 CEST | Press release
Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price
ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline ® Autogel ® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 07:00:00 CEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel®(lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatmen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom